Evidence map›Paper›PMID 31950675›Full record

ArticleFEBS open bio2020

Multimeric fusion single-chain variable fragments as potential novel high-capacity ligands.

Laila I Sakhnini, Anja K Pedersen, Maria B Dainiak, Leif Bülow

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Laila I SakhniniGlobal Research Technologies, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0002-1209-3078
Anja K PedersenChemistry, Manufacturing and Control, Novo Nordisk A/S, Copenhagen, Denmark.
Maria B DainiakGlobal Research Technologies, Novo Nordisk A/S, Copenhagen, Denmark.
Leif BülowDivision of Pure and Applied Biochemistry, Lund University, Lund, Sweden.
Lund University · SENovo Nordisk (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In basic and applied biotechnology, design of affinity ligands has become essential for high-capacity applications such as affinity-based downstream processes for therapeutic molecules. Here, we established a proof-of-concept for the use of multimeric fusion single-chain variable fragment (scFvs) as high-capacity ligands in affinity adsorbents. Mono- and di/tri-scFvs separated by Pro-rich negatively charged linkers were designed, produced, and immobilized to 6% cross-linked agarose beads. Frontal binding experiments with a target protein of 50 kDa resulted in up to 20 mg·mL

Indexed as

AdsorptionAnimalsBinding SitesCHO CellsChromatography, AffinityCricetulusCross-Linking ReagentsHEK293 CellsHumansLigandsPorosityProtein MultimerizationRecombinant Fusion ProteinsSepharoseSingle-Chain AntibodiesCross-Linking ReagentsLigandsRecombinant Fusion ProteinsSepharoseSingle-Chain Antibodiesaffinity chromatographybinding capacitypeptide linkerrecombinant fusion proteinsingle-chain variable fragment

Identifiers

PMID31950675
PMCPMC7137789
OpenAlexW2998792755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.